Resource Sharing for MAT Services in Lieu of COVID-19
MEDICATION ASSISTED TREATMENT ECHO
This interactive web-based program provides essential guidelines and steps to implementing and integrating a successful MAT program into an outpatient primary care setting. The MAT program aims to improve access for patients suffering from opioid use disorder.
- Diagnosing Opioid Use Disorder
- Types of medications (naltrexone vs. buprenorphine) and requirements for each (labs, monitoring, etc.)
- Buprenorphine induction maintenance, relapse and tapering protocols
- Referral process, clinic flow
- Opiate withdrawal-treatment
- Drug screens
- Controlled substance agreement
- Multi-party consents
- Prior authorization requirements for buprenorphine (documentation, barriers, etc.)
- Clinic and community integration
The purpose is to inform clinic members (admin, providers, nursing, etc.) on how to successfully integrate a MAT program into an outpatient primary care setting. The mission is to help centers and clinics set up primary care based MAT to improve access for patients suffering from opioid use disorder across the state of Iowa.
Professional Practice Gap
In response to the COVID-19 public health emergency declared by the Secretary of Health and Human Services, the Drug Enforcement Administration (DEA) has adopted policies to allow DEA-registered practitioners to prescribe controlled substances without having to interact in-person with their patients. The DEA has provided a decision tree which addresses prescribing controlled substances; however, it does not address administering or direct dispensing of controlled substances, including by narcotic treatment programs (OTPs) or hospitals. These policies are effective beginning March 31, 2020, and will remain in effect for the duration of the public health emergency, unless DEA specifies an earlier date.
This decision tree merely summarizes the policies for quick reference and does not provide a complete description of all requirements. Full details are on DEA’s COVID-19 website, and codified in relevant law and regulations.
- Provide essential guidelines and steps to implement a successful MAT program into primary care setting.
- Share resources for the treatment of MAT patients during the COVID-19 pandemic.
Iowa Primary Care Association
Relevant to the content of this educational activity, Ms. Miller does not have a financial relationship with commercial interest companies to disclose.
Gagan Lamba, MA, MS, MBA, CSM
Iowa Primary Care Association
Nicole Gastala, MD
Physician, Primary Health Care, Inc.
- Residency: University of Iowa
- Medical School: Loyola University Stritch School of Medicine
- Board Certification: American Board of Family Medicine
Relevant to the content of this education activity, the speakers indicated they do not have a financial relationships with commercial interest companies to disclose.
Peoples Community Health Clinic, Waterloo
Relevant to the content of this education activity, Ms. Henderson indicated she does not have a financial relationships with commercial interest companies to disclose.
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 1.25 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and Primary Health Care, Inc. DMU is accredited by IMS to provide continuing medical education for physicians. DMU designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 1.25 continuing education contact hour(s). No partial credit awarded.
- Other healthcare professionals: This live activity is designated for 1.25 AMA PRA Category 1 Credit(s)TM.
No commercial interest provided financial support for this continuing education activity.
Relevant to the content of this educational activity, the planning committee members and speaker indicated they have no financial relationships with commercial interests to disclose. The speaker(s) will disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director. Firms providing financial support did not have input in these areas.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 1.25 AMA PRA Category 1 Credits™
- 1.25 AOA Category 2A
- 1.25 CE Contact Hour(s)
- 1.25 IBON